​Join us for an exclusive evening at Deep Tech Week’s Biotech Summit, where world-leading scientists, engineers, and founders are redefining the frontiers of medicine and programmable biology.

​This summit brings together pioneers in targeted therapeutic delivery, gene therapy platforms, protein and genomic language and deep learning models, AI, diagnostics & theranostics, advanced transcriptomic analytics, and next-generation automation. Explore the breakthroughs enabling truly personalized, predictive, and curative care across rare disease, oncology, immune and metabolic disorders, and beyond.

​Highlights include:

• ​Fireside chats with industry and scientific leaders on the future of personalized and precision medicine, gene therapy, and platform commercialization

• ​Keynote from Stanford’s James Zou, PhD: “AI Scientist Agents to Accelerate Drug Discovery and Development”

• ​Lightning talks from experts in protein design AI, microfluidics, lab automation, digital diagnostics, surgical AI, and immunometabolism drug discovery

• ​Networking with top founders, investors, academics, and R&D decision-makers

​If you’re building, investing in, or partnering across biotech, digital health, or enabling platform tech, this summit is your chance to engage with the minds shaping the next decade of curative medicine. If you're an investor, bring your checkbook, and learn about the hottest startups in the space.

​For questions, contact dre@ligandal.com (Follow on X)

​AGENDA

​5:30 PM — Opening Remarks

​Welcome and Summit Overview

​Matt O’Brien, JD (Pillsbury Winthrop Shaw Pittman LLP)

​Andre Watson (Ligandal)

​5:40 PM — Enabling the Future of Personalized, Precision, and Predictive Medicine – How Delivery is the Final Frontier of Curative Medicine

​Andre Watson (CEO & Founder, Ligandal)

​5:50 PM — Fireside Chat: Platforms & Personalized Medicine – Barriers & Opportunities

​Nicole Fay, PhD (Nutcracker Therapeutics) and Andre Watson (Ligandal)

​6:05 PM — Fireside Chat: Personalized Medicine, the Future of Gene Therapy, and Market Evolution

​Emily Capra, PhD (McKinsey & Company) and Andre Watson (Ligandal)

​6:25 PM — Break

​6:30 PM — Keynote: AI Scientist Agents to Accelerate Drug Discovery and Development

​James Zou, PhD (Stanford University)

​Lightning Talks

​7:00 PM — AlphaFold2 Was Just the Beginning—Tackling Protein Dynamics and Function with AI

​Gina El Nesr, ABD (Stanford Biophysics)

​7:15 PM — Unleashing 1,000,000x Lab Productivity with AI-Powered Automation

​Ainur Nygmet (Faberge Labs)

​7:30 PM — See (exactly) what you treat: Designing new halogen radio-theranostics for the treatment of solid tumors

​Louis Metzger (dGenThera)

​7:45 PM - AI for Automating Surgical Outcomes in Orthopaedics and Beyond

​Adrian Killan (Mango Medical)

​8:00 PM — Inapill: Immunometabolism-Targeted Small Molecules for Autoimmunity

​Greg Timblin, PhD (Inapill)

​8:15 PM — Beyond pills and infusions: Building hardware that treats cancer

​Vivek Sharma, MS, ME, MBA (Asha Medical)

​8:30 PM — The present, past, and future of blood testing

​Michael Dubrovsky (SiPhox)

​8:45 PM — Closing Remarks

​Call-to-Action and Networking - Invitation to VIP Afterparty

​Andre Watson (Ligandal)

​SPEAKER BIOGRAPHIES

​James Zou, PhD

​Associate Professor, Biomedical Data Science, CS and EE, Stanford University

​AI for science; Faculty director of Stanford AI for Health; Overton Prize, Sloan Fellowship, 2x Chan-Zuckerberg Investigator.

​Developer of robust machine-learning frameworks for biotech applications; specializes in reliable AI models for protein sequence–function prediction.

​Andre Watson

​CEO & Founder, Ligandal

​Inventor of 88 patents, Forbes 30 Under 30 (Healthcare 2021); biomedical engineer and nanoscientist pioneering peptide-based targeted delivery for gene and drug therapies including CRISPR and mRNA.

​Nicole Fay, PhD

​Senior Director, Alliance Management, Nutcracker Therapeutics

​Molecular biologist focused on drug discovery and design for novel RNA therapeutics, making medicine more accessible and individualized.

​Gina El Nesr, ABD

​PhD Candidate, Biophysics, Stanford University

​Develops deep-learning methods for de novo protein design, enzymatic function, allostery, and modeling protein dynamics for new-to-nature mechanisms.

​Louis Metzger, PhD

​Co-Founder & CEO, dGenThera

​Louis Metzger is Co-founder and CEO of dGenThera, a radiopharmaceutical startup that leverages novel halogen chemistry to design theranostics for the treatment of solid tumors. He spent several years at Novartis Pharma and subsequently held leadership roles in synthetic biology and gene therapy startups. He is passionate about contributing to healthspan extension, particularly for cancer survivors, by developing targeted radiotherapeutics that can induce long-term remission while minimizing late-onset damage to healthy tissues.

​Emily Capra, PhD

​Partner & Head of New Modalities Service Line, McKinsey & Company

​Leads life-science R&D strategy for novel modalities, guiding pharma and biotech on commercializing next-generation therapies. AB Princeton, PhD MIT, Postdoc Caltech.

​Ann (Ainur) Nygmet

​Founder, Faberge Labs

​Engineer turned founder dedicated to revolutionizing lab automation with intelligent AI assistance. Ainur has successfully automated over 50 complex methods in cancer drug discovery pipelines and is passionate about freeing researchers from repetitive tasks and accelerating scientific breakthroughs. Her expertise lies in bridging the gap between biology and robotics to drive innovation in the lab.

​Michael Dubrovsky

​Co-Founder & CPO, SiPhox Health

​Materials chemist and entrepreneur building a chip-based at-home blood-testing device; former developer of photonic computing for cryptography.

​Adrian Killan

​CEO, Mango Medical

​Building AI platforms that automate surgical outcome predictions for orthopaedics and beyond, merging deep learning with personalized surgical interventions.

​Greg Timblin, PhD

​CEO, Inapill

​Developing first-in-class small molecule therapeutics targeting immunometabolism for improved treatment of inflammatory and autoimmune diseases; based at the Bakar BioEnginuity Hub, UC Berkeley.

​Vivek Sharma, MS, ME, MBA

​Co-Founder & CEO, Asha Medical

​20+ years in bioelectronic device development; leads a wearable immunotherapy platform for cancer; brings multiple FDA-approved devices to market.

​Matt O’Brien, JD

​Counsel, Pillsbury Winthrop Shaw Pittman LLP

​Legal advisor to Ligandal; counsel at Pillsbury Law

​See our previous NYC Biotech Summit here:

​Ligandal: Future of Biotech Summit

​This event is part of Deep Tech Week. Create a free profile at deep-tech-week.com/register to help hosts approve your registration and build your schedule for the week.